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Abstract 
Poorly water soluble compounds have solubility and dissolution 
related bioavailability problems. The present review deals in detail 
about solid dispersion technology and its manufacturing techniques 
at laboratory and industrial level. This highlight about various 
hydrophilic polymers used in this technique to enhance solubility of 
poorly soluble drugs. It also discusses about modern characterization 
technique to characterize solid dispersion. In this review, it is 
intended to discuss the recent advances related on the area of solid 
dispersion technology.    
Keywords: Solid dispersion; Carriers; Solubility; Dissolution; 
Bioavailability.  
Introduction 
The solubility of a drug is a key determinant of 
its oral bioavailability and permeability. There 
have always been certain drugs for which 
solubility has presented a challenge to the 
development of a suitable formulation for oral 
administration. Examples such as griseofulvin, 
digoxin, phenytoin, sulphathiazole and 
chloramphenicol come immediately to mind. 
With the recent advent of high throughput 
screening of potential therapeutic agents, the 
number of poorly soluble drug candidates has 
risen sharply and the formulation of poorly 
soluble compounds for oral delivery now presents 
one of the most frequent and greatest challenges 
to formulation scientists in the pharmaceutical 
industry [1, 2]. Therefore formulation approaches 
are being explored to enhance bioavailability of 
poorly water-soluble drugs. One such formulation 
approach that has been shown to significantly 
enhance absorption of such drugs is to formulate 
solid dispersion. 
 
Scientists gave different explanations of Solid 
dispersion. Chiou and Riegelman [3] defined the 
term solid dispersion as “a dispersion involving 
the formation of eutectic mixtures of drugs with 
water soluble carriers by melting of their physical 
mixtures”. Sekiguchi and Obi [4] suggested that 
the drug presented in a eutectic mixture in a 
microcrystalline state, after few years Goldberg et 
al.[5] reported that all drug in solid dispersion 
might not necessarily be presents in a 
microcrystalline state, a certain fraction of the 
drug might be molecular dispersion in the matrix, 
thereby forming a solid solution. 
 
The term solid dispersion refers to a group of 
solid products consisting of at least two different 
components, generally a hydrophilic matrix and a 
hydrophobic drug. The matrix can be either 
crystalline or amorphous. The drug can be 
dispersed molecularly, in amorphous particles 
(clusters) or in crystalline particles by melting or 
solvent method. Therefore, based on their 
molecular arrangement, different types of solid 
dispersions (SDs) can be distinguished. They are 
described in Table 1. 
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Table 1: Classification of solid dispersions in six subtypes. 
Solid 
Dispersion 
Type Matrix* Drug** Remarks No. of  
phases 
Reference 
I  Eutectics C  C the first type of solid dispersions 
prepared 
2 3 
II  Amorphous 
precipitations 
in crystalline 
matrix 
C A rarely encountered  2 6, 7 
III  Solid 
solutions 
     
 Continuous 
solid solutions 
C  M  miscible at all compositions, never 
prepared  
1 5 
 Discontinuous 
solid solutions 
C M partially miscible,  2 4 
 Substitutional 
solid solutions 
C M molecular diameter of drug (solute) 
differs less than 15% from matrix 
(solvent) diameter. In that case the 
drug and matrix are substitutional. 
Can be continuous or discontinuous. 
When discontinous: 2 phases even 
though drug is molecularly 
dispersed 
1 or 2 8, 9 
 Interstitial 
solid solutions 
C M drug (solute) molecular diameter 
less than 59% of matrix (solvent) 
diameter. Usually limited 
miscibility, discontinous. Example: 
Drug in helical interstitial spaces of 
PEG. 
2 3, 10 
IV   Glass  
suspension 
A  C particle size of dispersed phase 
dependent on cooling/evaporation 
rate. Obtained after crystallization 
of drug in amorphous matrix 
2 3, 11 
V  
 
Glass 
Suspension 
A A particle size of dispersed phase 
dependent on cooling/evaporation 
rate many solid dispersions are of 
this type 
2 3, 11 
VI  
 
Glass solution A M requires miscibility/solid solubility, 
complex formation or upon fast 
cooling/evaporation during 
preparation, many (recent) examples 
especially with PVP 
1 12 
*: A: matrix in the amorphous state 
C: matrix in the crystalline state 
**: A: drug dispersed as amorphous clusters in the matrix 
C: drug dispersed as crystalline particles in the matrix 
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Mechanism of Dissolution  
Management of the drug release profile using 
solid dispersions is achieved by manipulation of 
the carrier and solid dispersion particles 
properties. Parameters, such as carrier molecular 
weight, composition, drug crystallinity, particle 
porosity and wettability, when successfully 
controlled can produce improvements in 
bioavailability [13,14]. 
 
Particles with reduced particle size 
Molecular dispersions, as solid dispersions, 
represent the last state on particle size reduction, 
and after carrier dissolution the drug is 
molecularly dispersed in the dissolution medium. 
Solid dispersions apply this principle to drug 
release by creating a mixture of a poorly water 
soluble drug and highly soluble carriers. A high 
surface area is formed, resulting in an increased 
dissolution rate and consequently improved 
bioavailability [15, 16]. 
 
Particles with improved wettability 
A strong contribution to the enhancement of drug 
solubility is related to the drug wettability [17]. It 
has been suggested that the presentation of 
particles to the dissolution medium as physically 
separate entities may reduce aggregation. In 
addition, many of the carriers used for solid 
dispersions may have some wetting properties; 
hence improved wetting may lead to reduced 
agglomeration and increased surface area [18]. 
 
Particles with higher porosity 
 
Particles in solid dispersions have been found to 
have a higher degree of porosity [19].The 
increase in porosity also depends on the carrier 
properties; for instance, solid dispersions 
containing linear polymers produce larger and 
more porous particles than those containing 
reticular polymers and, therefore, result in a 
higher dissolution rate. The increased porosity of 
solid dispersion particles also hastens the drug 
release profile [20]. 
 
 
Drugs in amorphous state 
Poorly water soluble crystalline drugs, when in 
the amorphous state tend to have higher solubility 
[21, 22] The enhancement of drug release can 
usually be achieved using the drug in its 
amorphous state, because no energy is required to 
break up the crystal lattice during the dissolution 
process [23]. In solid dispersions, drugs are 
presented as supersaturated solutions after system 
dissolution, and it is speculated that, if drugs 
precipitate, it is as a metastable polymorphic 
form with higher solubility than the most stable 
crystal form [14, 16].  
 
Disadvantages OF Solid Dispersions  
Despite extensive expertise with solid 
dispersions, they are not broadly used in 
commercial products, mainly because there is the 
possibility that during processing (mechanical 
stress) or storage (temperature and humidity 
stress) the amorphous state may undergo 
crystallization [24-26]. The effect of moisture on 
the storage stability of amorphous 
pharmaceuticals is also a significant concern, 
because it may increase drug mobility and 
promote drug crystallization [27]. Moreover, 
most of the polymers used in solid dispersions 
can absorb moisture, which may result in phase 
separation, crystal growth or conversion from the 
amorphous to the crystalline state or from a 
metastable crystalline form to a more stable 
structure during storage. This may result in 
decreased solubility and dissolution rate [28]. 
Therefore, exploitation of the full potential of 
amorphous solids requires their stabilization in 
solid state, as well as during in vivo performance. 
Another drawback of solid dispersions is their 
poor scale-up for the purposes of manufacturing.  
 
Pharmaceutical Applications of Solid 
dispersion: 
The pharmaceutical applications of solid 
dispersions technique are numerous. They may be 
employed- 
1. To enhance the absorption of drug;  
2. To obtain a homogeneous distribution of a 
small amount of drug in solid state;  
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3. To stabilize unstable drugs and protect 
against decomposition by processes such as 
hydrolysis, oxidation, racemization, photo 
oxidation etc.;  
4. To dispense liquid or gaseous compounds;  
5. To formulate a fast release priming dose in 
a sustained release dosage form;  
6. To formulate sustained release preparation 
of soluble drugs by dispersing the drug in 
poorly soluble or insoluble carrier; 
7. To reduce side effects-(a) the binding 
ability of drugs for example to the 
erythrocyte membrane is decreased by 
making its inclusion complex, (b) the 
damage to the stomach mucous membranes 
by certain non-steroidal anti-inflammatory 
drugs can be reduced by administration as 
an inclusion compound; 
8. To mask unpleasant taste and smell. The 
very unpleasant taste of anti-depressant 
famoxetine hindered the development of 
oral liquid formulations. The bitter taste 
was greatly suppressed when the solid 
complex of famoxetine was formulated as 
aqueous suspension; 
9. To convert liquid compounds into 
formulations. Liquid drugs can be 
manufactured as solid drug formulations 
such as powders, capsules or tablets e.g., 
unsaturated fatty acids, essential oils, 
nitroglycerin, benzaldehyde, prostaglandin, 
clofibrate etc. 
 
Method of Preparation 
Various preparation methods for solid dispersions 
have been reported in literature. Some laboratory 
and industrially feasible methods are summarized 
here: 
 
Fusion method 
The fusion method is sometimes referred to as the 
melt method, which is correct only when the 
starting materials are crystalline. Sekiguchi et al. 
[4] were the first to use a melting method 
consisting of melting the drug within the carrier 
followed by cooling and pulverization of the 
obtained product. A common adaptation to the 
melting phase consists of suspending the active 
drug in a previously melted carrier, instead of 
using both drug and carrier in the melted state, 
therefore reducing, the process temperature. To 
cool and solidify the melted mixture, several 
processes such as ice bath agitation, stainless 
steel thin layer spreading followed by a cold 
draught, solidification on petri dishes at room 
temperature, inside a dessicator, spreading on 
plates placed over dry ice, immersion in liquid 
nitrogen or stored in a dessicator were used. After 
cooling, the mixture must be pulverized regarding 
its handling [29-31].  
 
The fusion process is technically the less difficult 
method of preparing dispersions provided the 
drug and carrier are miscible in the molten state. 
However, the use of high temperatures, and the 
fact that several drugs can be degraded by the 
melting process, can be a limitation of this 
method. The incomplete miscibility between drug 
and carrier that may occur, because of the high 
viscosity of a polymeric carrier in the molten 
state, is another limitation of this process [32-34]. 
To avoid the melting method limitations, several 
modifications, like hot-stage extrusion, 
MeltrexTM or melt agglomeration were introduced 
to the original method. 
 
Solvent method 
The first step in the solvent method is the 
preparation of a solution containing both matrix 
material and drug. The second step involves the 
removal of solvent(s) resulting in formation of a 
solid dispersion. Mixing at the molecular level is 
preferred, because this leads to optimal 
dissolution properties [35, 36]. 
 
With the discovery of the solvent method, many 
of the problems associated with the melting 
method were solved. For example, it was then 
possible to form solid dispersions of thermolabile 
substances. Likewise, many polymers that could 
not be utilized for the melting method due to their 
high melting points (e.g. PVP) could be now 
considered as carrier possibilities. As a result, for 
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many years the solvent method was the method 
of choice for polymer-based systems.  
 
Using the solvent method, the pharmaceutical 
engineer faces many challenges. The solvent-
based process uses organic solvent to dissolve 
and intimately disperse the drug and carrier 
molecule. Identification of a common solvent for 
both drug and carrier can be problematic and 
complete solvent removal from the product can 
be a lengthy process. Moreover subtle alterations 
in the concentrations used for solvent evaporation 
may lead to large changes in the product 
performance. In addition large volumes of 
solvents are generally required which can give 
rise to toxicological problems. 
 
With time, however, the ecological and 
subsequent economic problems associated with 
the use of organic polymers began to make 
solvent-based methods more and more 
problematic. For these reasons, hot melt extrusion 
is the current method of choice for the 
preparation of solid dispersions. Many 
investigators studied solid dispersion of 
felodipine [37] meloxicam [38], naproxen [39, 
40], atenolol [41], and nimesulide [42] using 
solvent evaporation technique.  
 
Hot melt extrusion  
Hot-stage extrusion (HME) consists of the 
extrusion, at high rotational speed, of the drug 
and carrier, previously mixed, at melting 
temperature for a small period of time. The 
resulting product is then collected after cooling at 
room temperature and milled [43-45]. A 
reduction in processing temperature can be 
achieved by the association of hot-stage extrusion 
with the use of carbon dioxide as a plasticizer 
[46, 47], which broadens the application of hot-
stage extrusion to thermally labile compounds. 
Solid dispersions of para-amino salicylic 
acid/ethylcellulose [48], itraconazole/ PVP [49] 
and itraconazole/ethylcellulose [50] were 
successfully prepared by this technique. 
Moreover, it was observed that solid dispersions 
of itraconazole/inutec SPI prepared by hot-stage 
extrusion presented itraconazole in a fully glassy 
state, whereas it was only partially glassy in solid 
dispersions prepared by spray drying [51] 
 
HME also offers several advantages over 
traditional pharmaceutical processing techniques 
including the absence of solvents, few processing 
steps, continuous operation, more possibility of 
the formation of solid dispersions and improved 
bioavailability [52].  
 
An amorphous solid dispersion of itraconzole 
with HPMC was formed from milled melt 
extrudate and resulted in a significantly increased 
dissolution rate compared with the physical 
mixture; the formulation was found chemically 
and physically stable for periods in excess of 6 
months [53, 54]. The tablets formed by 
compressing milled melt-extruded glassy powder 
with additional excipients showed high oral 
bioavailability [55]. 
 
Electrostatic spinning method 
In this process, a liquid stream of a drug/polymer 
solution is subjected to a potential between 5 and 
30 kV. When electrical forces overcome the 
surface tension of the drug/polymer solution at 
the air interface, fibers of submicron diameters 
are formed. As the solvent evaporates, the formed 
fibers can be collected on a screen to give a 
nonwoven fabric, or they can be collected on a 
spinning mandril. The fiber diameters depend on 
surface tension, dielectric constant, feeding rate, 
and electric field strength. Electrospun samples 
dissolved dependent on the type of formulation 
and the drug:polymer ratio. The technique has 
been successfully used in the pharmaceutical 
industry for the preparation of solid dispersions 
[56-58]. 
 
Water-soluble polymers would be useful in the 
formulation of immediate release dosage forms, 
and water-insoluble (both biodegradable and 
nonbiodegradable) polymers are useful in 
controllable dissolution properties. Fabrics 
generated by water-soluble carriers could be used 
in oral dosage formulations by direct 
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incorporation of the materials into a capsule. 
Itraconazole/HPMC nanofibers have been 
prepared by using this technique [59, 60].  
 
Direct capsule filling 
Direct filling of hard gelatin capsules with the 
liquid melt of solid dispersions avoids grinding-
induced changes in the crystallinity of the drug. 
The filling of hard gelatin capsules has been 
feasible in molten dispersions of triamterene-PEG 
1500 using a Zanasi LZ 64 capsule-filling 
machine (Zanasi Co, Bologna, Italy) [61, 62]. 
This molten dispersion forms a solid plug inside 
the capsule on cooling to room temperature, 
reducing cross-contamination and operator 
exposure in a dust-free environment, better fill 
weight and content uniformity was obtained than 
with the powder-fill technique. However, PEG 
was not a suitable carrier for the direct capsule-
filling method as the water-soluble carrier 
dissolved more rapidly than the drug, resulting in 
drug-rich layers formed over the surface of 
dissolving plugs, which prevented further 
dissolution of the drug [63]. A surfactant must be 
mixed with the carrier to avoid formation of a 
drug-rich surface layer (eg, polysorbate 80 with 
PEG, phosphatidylcholine with PEG [64, 65]. 
The temperature of the molten solution should 
not exceed above 70°C because it might 
compromise the hard-gelatin capsule shell. 
 
Supercritical fluid (SCF) process 
Another novel nanosizing and solubilisation 
technology whose application has increased in 
recent years is particle size reduction via 
supercritical fluid (SCF) processes. Supercritical 
fluids are fluids whose temperature and pressure 
are greater than its critical temperature (Tc) and 
critical pressure (Tp), allowing it to assume the 
properties of both a liquid and a gas. At near-
critical temperatures, SCFs are high 
compressible, allowing moderate changes in 
pressure to greatly alter the density and mass 
transport characteristics of a fluid that largely 
determine its solvent power [66, 67]. Once the 
drug particles are solubilised within SCF, they 
may be recrystallised at greatly reduced particle 
sizes. The flexibility and precision offered by 
SCF processes allows micronisation of drug 
particles within narrow ranges of particle size, 
often to sub-micron levels. Current SCF 
processes have demonstrated the ability to create 
nanoparticulate suspensions of particles 5-
2,000nm in diameter. Several pharmaceutical 
companies, such as Nektar Therapeutics and 
Lavipharm, are specialising in particle 
engineering via SCF technologies for particle size 
reduction and solubility enhancement [68, 69]. 
 
Several methods of SCF processing have been 
developed to address individual aspects of these 
shortcomings, such as precipitation with 
compressed antisolvents process (PCA), solution 
enhanced-dispersion by SCF (SEDS), 
supercritical antisolvents processes (SAS) and 
aerosol supercritical extraction system (ASES) 
[70, 71]. 
 
It has been known for more than a century that 
supercritical fluids (SCFs) can dissolve 
nonvolatile solvents, with the critical point of 
carbon dioxide, the most widely used 
supercritical fluid. SCF technology offers 
tremendous potential, as it is safe, 
environmentally friendly, and economical. The 
low operating conditions (temperature and 
pressure) make SCFs attractive for 
pharmaceutical research. 
 
Lyophillization technique 
Lyophillization has been thought of a molecular 
mixing technique where the drug and carrier are 
co dissolved in a common solvent, frozen and 
sublimed to obtain a lyophilized molecular 
dispersion [72].  This technique was proposed as 
an alternative technique to solvent evaporation. 
An important advantage of freeze drying is that 
the drug is subjected to minimal thermal stress 
during the formation of the solid dispersion. 
However, the most important advantage of freeze 
drying is that the risk of phase separation is 
minimized as soon as the solution is vitrified. 
Betageri et al. [73], Topalogh et al. [74], Badry et 
al. [75] and Fathy et al. [76] have successfully 
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investigated the potential applications of 
lyophilization technique using glyburide, 
ketoprofen, meloxicam, amylobarbitone in solid 
dispersion manufacturing. 
 
An even more promising drying technique is 
spray-freeze drying. The solvent is sprayed into 
liquid nitrogen or cold dry air and the frozen 
droplets are subsequently lyophilized. The large 
surface area and direct contact with the cooling 
agent result in even faster vitrification, thereby 
decreasing the risk for phase separation to a 
minimum. Moreover, spray freeze drying offers 
the potential to customize the size of the particle 
to make them suitable for further processing or 
applications like pulmonary or nasal 
administration. 
 
Drooge et al. [77] suggested spray freeze-drying 
process to produce 9- tetrahydrocannabino 
containing inulin based solid dispersions with 
improved incorporation of tetrahydrocannabino 
in inulin. 
 
Spray drying 
Today, spray drying finds great utility in 
pharmaceutical industry because of the rapid 
drying and specific characteristics such as 
particle size and shape of the final product. In 
addition, it is simple and cost effective, as it is 
30-50 times less expensive than freeze-drying. It 
is an established method that is initiated by 
atomizing suspensions or solutions into fine 
droplets followed by a drying process. The 
process allows production of fine, dust free 
powder as well as agglomerated one to precise 
specifications. The operating conditions and 
dryer design depends upon the drying 
characteristics of the product and require powder 
specifications [78-80].  
 
The spray drying technique is a useful method to 
obtain spherical particle and narrow distribution. 
The role of porous materials such as calcium 
silicate, controlled pore glass and porous 
cellulose is appreciated to formulate solid 
dosages forms because they confer special 
characteristics such as decrease of melting point 
and a decrease in the crystallinity of drug 
entrapped in pores. In addition, porous material 
controls polymorphs and stabilizes meta-stable 
crystals in solid dispersions under sever storage 
conditions. Moreover, porous silica has been 
reported to improve solubility and dissolution 
rates of indomethacin and tolbutamide [81, 82]. 
The frequent use of the organic solvent in spray 
drying pose problems such as residues in 
products, environmental pollution and operational 
safety as well as corporate problems such as 
capital investment. 
 
Solid dispersion of loperamide and PEG 6000 
were prepared by this technique [83]. The 
prepared SD(s) exhibited higher dissolution rates 
than that of pure crystalline loperamide. Chouhan 
et al. [84] studied the suitability of this technique 
for preparation of SD(s) of glibenclamide with 
polyglycolized glycerides. This study revealed 
the improvement in solubility, dissolution rates 
and in therapeutics efficacy of glibenclamide in 
SD(s). 
 
Carriers in solid dispersion  
Carriers, which are soluble and dissolve in water 
at a fast rate, are widely used in pharmaceutical 
formulations to enhance dissolution of drugs. The 
carriers which have been reported in literature are 
described in detail below. 
 
Polyethylene glycol  
Polyethylene glycols (PEGs) are polymers of 
ethylene oxide, with a molecular weight (MW) 
usually falling in the range 200 ± 3,00,000. Their 
solubility in water is generally good, but 
decreases with MW. A particular advantage of 
PEGs for the formation of solid dispersions is 
that they also have good solubility in many 
organic solvents. The melting point of the PEGs 
of interest lies under 65°C in every case (e.g. the 
m.p. of PEG 1000 is 30-40°C, the m.p. of PEG 
4000 is 50-58°C and the m.p. of PEG 20,000 is 
60-63°C) [85]. These relatively low melting 
points are advantageous for the manufacture of 
solid dispersions by the melting method. Even the 
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dissolution rate of a relatively soluble drug like 
carbamezapine can be improved by formulating it 
as a solid dispersion in PEG 6000.   
 
PEGs of MW 4000-6000 are the most frequently 
used for the manufacture of solid dispersions, 
because in this MW range the water solubility is 
still very high, but hygroscopy is not a problem 
and the melting points are already over 50°C. If a 
PEG with too low a MW is used, this can lead to 
a product with a sticky consistency that is 
difficult to formulate into a pharmaceutically 
acceptable product [86].  
 
Ozkan et al. [87] reported increasing solubility of 
etodolac with PEG 6000 as a carrier by melting 
method.  Similarly Dehghan and Jafar [88] 
studied meloxicam solid dispersions prepared by 
physical mixing, co-grinding and solvent 
evaporation methods with PEG 6000.  The 
enhanced dissolution rate of meloxicam by solid 
dispersion technique may be due to increased 
wettability and hydrophilic nature of carrier. 
 
Further drugs which exhibit elevated release rates 
when formulated as PEG 6000 solid dispersions 
include ofloxacin [89], silymerin [90], gliclazide 
[91],  dapsone [92] , mebendazole [93], Cisapride 
[94], Nitrendipine [95], oxazepam [96], 
valdecoxib [97], isosorbide dinitrate [98], 
zolpidem [99], piroxicam [100],  fenofibrate 
[101], glibenclamide [102], ketoprofen [103]. 
PEGs with higher MW have also been use with 
success e.g. products containing PEG 8000 [104] 
and PEG 10,000 [105] showed enhanced 
dissolution rates compared to the pure drug. 
 
Poly vinyl pyrrolidone 
Polymerization of vinylpyrrolidone leads to 
polyvinylpyrrolidone (PVP) of molecular weights 
ranging from 2500 to 3,000,000. These can be 
classified according to the K value [106]. Due to 
their good solubility in a wide variety of organic 
solvents, they are particularly suitable for the 
preparation of solid dispersions by the solvent 
method. Similarly to the PEGs, PVPs have good 
water solubility and can improve the wettability 
of the dispersed compound in many cases. 
Improved wetting and thereby an improved 
dissolution rate from a solid dispersion in PVP 
has been demonstrated for flufenamic acid [107]. 
The chain length of the PVP has a very 
significant influence on the dissolution rate of the 
dispersed drug from the solid dispersion. The 
aqueous solubility of the PVPs becomes poorer 
and viscosity lowers with increasing chain length. 
 
Solid dispersions of praziquantel (PZQ) 
containing varying concentrations of PVP with 
different MW (3000, 11,000 and 34,000) were 
prepared. The solubility of PZQ in the 
coprecipitate was greater when PVP of a smaller 
molecular weight was used [108]. An 
enhancement of 6.15-fold in dissolution rate of 
ipriflavone (IP) solid dispersion [109] was noted 
with PVP K-30 as that of IP alone  and 40 fold 
increase with piroxicam [110] when PVP K 17 is 
used. 
 
Further drugs which exhibit elevated release rates 
when formulated as PVP solid dispersions 
include diflunisal [111], nifedipine [112], 
tanshinone [113], cefuroxime axetil [114], 
flunarizine [115], daidzein [116], nitrendipine 
[117], ketoprofen [118], bicalutamide [119], 
quercetin [120], lansoprazole [121]. 
 
Urea 
Urea is the end product of human protein 
metabolism, has a light diuretic effect and is 
regarded as non-toxic. Its solubility in water is 
greater than 1 in 1 and it also exhibits good 
solubility in many common organic solvents. In 
one of the first bioavailability studies of solid 
dispersions, it was shown that sulphathiazole was 
better absorbed in rabbits when given as a 
eutectic with urea [4]. Similarly, Goldberg et al. 
[5] reported faster dissolution rates of 
chloramphenicol when prepared with urea as the 
carrier. Although urea is not often used as a 
carrier these days, it has been recently shown that 
the dissolution rate of the poorly soluble 
compound ofloxacin can be improved by more 
than three fold by incorporating it in coevaporate 
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with urea [122]. In the case of Rofecoxib [123] 
the release rate from urea dispersions was faster 
than from other carriers studied, including PEG 
4000. A increase in the dissolution rate of 
piroxicam [124] has also been achieved with 
urea; however, in this case PEG 4000 was far 
more effficient . Maheshwari [125] reported 
solubility enhancement by using urea as a 
hydrotropic agent. Verma investigated increased 
dissolution of flurbiprofen with urea and xylitol 
[126]. 
 
Sugars 
Although sugars and related compounds are 
highly water soluble but few sugars have toxicity 
issues, they are less suitable than other carriers 
for the manufacture of solid dispersions. The 
melting point of most sugars is high, making 
preparation by the hot melt method problematic, 
and their solubility in most organic solvents is 
poor, making it difficult to prepare coevaporates. 
Despite these drawbacks, several attempts to 
prepare solid dispersions using sugars and their 
derivatives have been reported.  
 
Lactose is useful as a carrier for the production of 
solid dispersions of drugs having a primary amide 
group in their structures like carbamazepine or 
ethenzamide prepared by melting and rapid 
cooling showed marked increase in dissolution 
same results were shown in study with naproxen 
[127, 128]. 
 
Chitosan, a derivative of the polysaccharide 
chitin which is formed by deacetylation at the N 
position, has also been used as a carrier in solid 
dispersions. Both chitosan and its salt form, 
chitosan glutamate, were able to improve the 
release of nifedipine by a factor of two to three 
compared to the drug powder [129]. In solid 
dispersion with 1:1 ratio oflaxacin to chitosan, 
showed as the best carrier for drug release [130]. 
Similar results were found with fenofibrate [131], 
oxazepam [132] and miconazole [133]. 
 
Mannitol, which has a melting point of 165-
168°C and decomposes only above 250°C, can be 
employed in some cases to prepare dispersions by 
the hot melt method. Improved release 
characteristics have been reported for sorbitol 
dispersions of several compounds, including 
nitrofurantoin [134], prednisolone [135], 
ofloxacin [136] and uresodeoxycholic acid [137]. 
In most of these cases, other carriers produced 
better results. Interestingly, nitrofurantoin 
showed better release from sorbitol than mannitol 
dispersions. Indeed, a dispersion of prednisolone 
in sorbitol released the drug faster than all other 
carriers tested, including PEG, PVP, urea and 
mannitol [138]. 
 
Emulsifiers 
The release behaviour of many drugs can also be 
improved through the use of emulsifying agents. 
Two mechanisms are possible here: improvement 
of wetting characteristics and solubilization of the 
drug. Owing to their potential toxicity problems, 
such as damage to mucosal surfaces, they are 
used in combination with another carrier. For 
example, the enhanced release of mefenemic acid 
from solid dispersions, using PEG 6000 with 
tween 20 [139]. An increase in 7 fold in solubility 
observed when solid dispersions  of nitrendipine 
were prepared by using a melting method with 
PEG 6000 and polysorbate 80 as carriers [140]. 
The fenofibrate solid dispersion tablets prepared 
by solvent-melting method using PEG 4,000 and 
sodium lauryl sulfate has showed increased 
release [141]. Shokri and Azami proved the effect 
of anionic (SLS), cationic (CTAB) and nonionic 
(Myrj 52) surfactants as carriers on enhanced 
dissolution rate of oxazepam. Surfactants are 
suitable carriers for low dose and very low water 
soluble drugs [142]. 
 
Poloxamers are nonionic triblock copolymers 
composed of a central hydrophobic chain of 
polyoxypropylene (poly(propylene oxide)) 
flanked by two hydrophilic chains of 
polyoxyethylene (poly(ethylene oxide)). Because 
of their amphiphilic structure, the polymers have 
surfactant properties that make them useful in 
industrial applications. Among other things, they 
can be used to increase the water solubility of 
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hydrophobic and oily substances or otherwise 
increase the miscibility of two substances with 
different hydrophobicities. For this reason, these 
polymers are commonly used in industrial 
applications, cosmetics and pharmaceuticals. 
 
Kwon and Kim [143] suggested pluronic F 127 
polymeric micelles could improve the oral 
bioavailability of genistein. Badry and Fathy used 
pluronic F 98 for dissolution enhancement of 
piroxicam [144]. Similar results like increased 
solubility and enhanced bioavailability have been 
showed by nifedipine and ebselen [145,146]. 
 
Chen et al. improved the dissolution and 
bioavailability of ABT-963, a poorly water-
soluble compound by preparing solid dispersion 
using Pluronic F-68 as a carrier by evaporation 
and hot melt method [147].  
 
The recently used surface-active carrier is 
Gelucire® 44/14 and other grades of Gelucire®. 
The carriers are prepared to have a high melting 
point but not more than 70°°C so as to 
compatible to be filled in hard gelatin capsule. 
The grades of Gelucire® is denoted by different 
number like 44/14 and 13, in that first digit 
denotes the melting point of carrier and second 
digit denote HLB value of carrier. Gelucire® 
44/14 is a mixture of glyceryl and PEG-1500 
ester of long-chain fatty acid and is official in 
European pharmacopoeia as a lauryl 
macrogolglycerides [148]. 
Dordunoo et al. [149] studied the effect of 
Gelucire® 44/14 for improving the solubility of 
temazepam in comparison with various poly 
ethylene glycol and shown large increase in its 
water solubility. Enhanced dissolution was 
observed with lornoxicam [150], tiaprofenic acid 
[151], thiocarboxanilide UC-781 [152] and 
carbamazepine [153] when gelucire 44/14 is used 
as surfactant alone and with other carriers. 
 
Bile salts and their derivatives are natural 
surfactants that are built from a steroidal skeleton 
in the liver and which are important for the 
emulsification of fats and oils in the diet. Like 
other surfactants, they enhance the wetting and 
solubility of many lipophilic substances, leading 
to an increase in the dissolution rate. Stoll et al. 
[154] demonstrated the ability of bile salts such 
as cholic acid, deoxycholic acid and lithocholic 
acid to improve not only the release but also the 
sedative effects of reserpine when given as a 
coevaporate. Likewise, the release of 
hydrocortisone can be enhanced by formulation 
as a solid dispersion in cholesterol and various 
cholesterol esters [155].  
 
Polyacrylates and polymethacrylates 
Polyacrylates and polymethacrylates are glassy 
substances that are produced by the 
polymerization of acrylic and methacrylic acid, 
and derivatives of these polymers such as esters 
amides and nitriles. In pharmaceuticals they are 
mostly used in coatings to modify the release of 
the drug from the dosage form. Commonly they 
are referred by the trade name Eudragit [156]. 
Among the eudragits  eudragit  E is often used to 
improve the release rate since it is soluble in 
buffer solutions at pH values up to 5 and swells at 
higher pH values, while eudragit  L can be used 
when it is desirable to avoid release in the 
stomach. Jun and Jeong observed improved 
dissolution of  atorvastatin calcium with eudragit 
E100 as a carrier [157].  
 
Cellulose derivative 
Celluloses are naturally occurring 
polysaccharides that are ubiquitous in the plant 
kingdom. They consist of high molecular weight 
unbranched chains, in which the saccharide units 
are linked by β-1,4-glycoside bonds. By 
appropriate alkylation, the cellulose can be 
derivatized to form methyl- (MC), hydroxypropyl 
(HPC), hydroxypropylmethyl (HPMC) and many 
other semi-synthetic celluloses. A further 
possibility for derivatization is the esterification 
of the cellulose to form compounds such as 
cellulose acetate phthalate (CAP) and 
hydroxypropylmethylcellulose phthalate 
(HPMCP) [158]. 
 
 
 
158
Sharma et al. International Journal of Drug Delivery 3 (2011) 149-170 
 
Suspension formulated employing paracetamol-
HPMC solid dispersions gave highest 
improvement in the dissolution  rate and 
dissolution efficiency of paracetamol [159]. 
Other drugs which exhibit faster release from 
solid dispersion in HPMC include the poorly 
soluble weak acids nilvadipine [160] and 
benidipine [161], Carbamezapine [162] and 
cisapride [163]. Yuasa et al. [164] carried out 
extensive studies of the influence of the chain 
length and proportion of HPC in the solid 
dispersion on the release behaviour of 
flurbiprofen. The release rate improved as the 
proportion of HPC was increased and when lower 
molecular weight HPCs were used as the carrier. 
 
Characterization of Solid Dispersion 
There have been several reports on the analysis of 
solid dispersions. A variety of techniques, such as 
XRPD, NMR, Raman and IR have been used to 
identify the crystal form in a wide selection of 
dosage forms, including tablets, capsules, 
ointments, suppositories and microspheres [165]. 
A small selection of the available literature will 
be discussed here.  
 
Powder Xray diffraction 
As a consequence of the importance of solid drug 
substance characterization, analytical tools such 
as X-ray diffractometry are usually employed in 
the pharmaceutical field. The detection of 
crystalline phases in mixed systems can be 
analyzed by powder X-ray diffraction. However, 
too much crystallinity causes brittleness. The 
crystallinity parts give sharp narrow diffraction 
peaks and the amorphous component gives a very 
broad peak. The ratio between these intensities 
can be used to calculate the amount of 
crystallinity in the material [166-170]. 
 
Differential scanning calorimetry (DSC) 
DSC is a well-known technique that measures 
heat flow into or out of a material as a function of 
time or temperature. Crystallinity can be 
determined with DSC by quantifying the heat 
associated with melting (fusion) of the material. 
Glass transitions may occur as the temperature of 
an amorphous solid is increased. This is due to 
the sample undergoing a change in heat capacity; 
no formal phase change occurs. As the 
temperature increases, an amorphous solid will 
become less viscous. At some point the 
molecules may obtain enough freedom of motion 
to spontaneously arrange themselves into a 
crystalline form. This is known as the 
crystallization temperature (Tc). This transition 
from amorphous solid to crystalline solid results 
in an exothermic peak in the DSC signal. As the 
temperature increases the sample eventually 
reaches its melting temperature (Tm). The 
melting process results in an endothermic peak in 
the DSC curve. 
 
The exact nature of the thermal transitions has to 
be determined with complementary methods such 
as microscopic observations, thermogravimetry, 
X-ray diffraction or spectroscopic techniques to 
distinguish [171-175]. 
 
Hot stage microscopy 
Hot stage microscopy is one of the oldest and 
most straightforward methods for studying phase 
transitions in crystals. Varying the temperature of 
a substance while viewing it under a microscope, 
often through crossed polarizers, provides a 
wealth of information about melting or 
recrystallization behavior as well as solid-state 
transformations. This technique also allows the 
detection of solvates by observing the evolution 
of a gas or liquid from a crystal. Novel 
polymorphs can be generated in this experiment 
either by high temperature transition of one form 
to another or by crystallization from the melt. 
Coupling hot stage microscopy with vibrational 
spectroscopy or DSC can further expand the 
utility of this method [176, 177]. 
 
Macroscopic techniques 
Macroscopic techniques measure mechanical 
properties that are different for amorphous and 
crystalline material can be indicative for the 
degree of crystallinity. Density measurements 
and dynamic mechanical analysis (DMA) 
determine the module of the elasticity and 
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viscisity and thus affected by the degree of 
crystallinity. 
 
Nuclear magnetic resonance spectroscopy  
Solid-state nuclear magnetic resonance (SS-
NMR) spectroscopy can be used to investigate 
polymorphism by probing the environments of 
atoms in the solid state; non-equivalent nuclei 
will resonate at different frequencies and these 
changes in chemical shift can often be connected 
with changes in conformation or chemical 
environment of the compound. 
 
SS-NMR is also useful because it is able to 
determine the number of crystallographically 
inequivalent sites in a unit cell. Unlike PXRD, 
SS-NMR spectroscopy is well-suited to studying 
amorphous forms of pharmaceuticals and solvates 
that are usually small to detect.  Collecting 
spectra at various temperatures is a powerful tool 
in understanding polymorphic transformations 
and molecular motion in the solid [178-180]. 
 
Vibrational spectroscopy 
Most prominent among the vibrational 
spectroscopic methods for polymorph 
identification are infrared and raman 
spectroscopy. Both techniques offer information 
on structure and molecular conformation in the 
solid state by probing vibrations of atoms. These 
methods are especially important for 
characterization of polymorphs because 
hydrogen-bonding patterns often differ among 
forms and the functional groups affected will 
display shifts of varying degrees. Other 
information gained from vibrational 
spectroscopies, which can be helpful in 
distinction of polymorphs, includes low energy 
lattice vibrations caused by differences in crystal 
packing.  
 
Infrared absorption spectroscopy has enjoyed the 
most use in polymorph investigations primarily 
because it is a robust technique available in most 
laboratories. Several limitations of the technique 
are worth considering especially for studies 
involving small quantities of sample or single 
crystals. These studies are most conveniently 
conducted by IR microscopy and this is the 
method of choice for studies on single crystals. 
However, an IR transparent substrate must be 
employed and it is difficult to collect spectra of 
all but the thinnest crystals due to transmittance 
issues. Substrate and sample transmittance issues 
can be circumvented by using attenuated total 
reflection (ATR) or diffuse-reflectance infrared 
(DRIFT) spectroscopy [181, 182]. 
 
Raman spectroscopy is a powerful light scattering 
technique used to diagnose the internal structure 
of molecules and crystals. In a light scattering 
experiment, light of a known frequency and 
polarization is scattered from a sample.  A raman 
spectrometer interfaced to a microscope has an 
additional advantage of being able to pinpoint 
small crystalline samples, which do not have to 
be removed from crystallization vials for 
analysis, thus eliminating sample preparation. In 
addition, the spatial resolution of raman 
microscopy  is limited by the wavelength of the 
visible light probe rather than infrared radiation, 
making this technique suitable for examining 
minute sample quantities in complex matrices. 
[183, 184] 
 
Water vapour sorption 
Water vapour sorption can be used to 
discriminate between amorphous and crystalline 
material when the hygroscopicity is different. The 
method requires accurate data of the 
hygroscopicity of both completely crystalline and 
completely amorphous samples. In some studies 
amorphous material were plasticized by water 
sorption and crystallized during the experiment. 
However crystallization can be accompanied by 
expel of water depending on the degree of 
hydration of crystalline material [185]. 
 
Conclusion 
The solid dispersion method is one of the 
effective approaches to achieve the goal of 
solubility enhancement of poorly water-soluble 
drugs. Various techniques, described in this 
review, are successfully used for the preparation 
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of solid dispersion in the bench and lab scale and 
can be used at industrial scale also. With future 
development of this technology, solid dispersions 
will continue to enable novel applications in drug 
delivery and solve problems associated with the 
delivery of poorly soluble drugs. 
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